Non-Small Cell Lung Cancer: KOL Insight

June 2015 | | ID: NC4ED9311A4EN
FirstWord

Abstracts

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting KRAS-mutation positive disease.

The treatment of advanced NSCLC has seen substantial advances in the past decade and this progress is set to continue, propelled by the development of checkpoint inhibitors and new targeted therapies. The second-line space is set to undergo a paradigm shift driven by the emergence of the PD-1 and PD-L1 inhibitors as well as new targeted agents. In the longer term the first-line setting will diversify as new products, including checkpoint inhibitors, vie for approval in this lucrative space.

Non-Small Cell Lung Cancer: KOL Insight presents a comprehensive qualitative review of targeted therapies in the market for advanced NSCLC with an emphasis on current and future treatment pathways.

Research Objectives

• Which drugs constitute the first- and subsequent-line treatments of choice for patients in the following segments: EGFRm+, ALK translocation positive and EGFR mutation/ALK translocation negative? Which product attributes contribute to this preference?
• How BMS’s Opdivo, Astellas’/Roche’s Tarceva, AstraZeneca’s Iressa, Boehringer Ingelheim’s Gilotrif and Vargatef, Pfizer’s Xalkori, Novartis’ Zykadia, Roche’s Avastin and Eli Lilly’s Cyramza are perceived by the medical community in terms of efficacy, tolerability, ease of administration, and other product attributes, and how they compare with other current and pipeline treatment options.
• Which recently completed or ongoing clinical trials (e.g. CheckMate-057, CheckMate-026, CheckMate-227, KEYNOTE-021, OAK, PACIFIC, LUX-Lung 7, AURA3, TIGER-1, ALEX, AvaALL, SELECT-1 and HER3-Lung) have the greatest potential to impact prescribing trends, and how will the results impact the future treatment of NSCLC.
• What do pipeline targeted therapies for NSCLC need to show in order to become the treatment of choice in a specific patient segment and line of therapy and is it likely the product will meet these requirements?
• How the use of each current and pipeline targeted NSCLC product will change in the future in terms of patient segment, line of therapy and preference.
• What pipeline products for NSCLC will need to show in terms of efficacy and tolerability endpoints to compete effectively, and what the likelihood is that the pipeline products will achieve those endpoints.
• Which pipeline products are the most promising and how they will impact current players in the market (e.g. Merck & Co.’s Keytruda, Roche’s atezolizumab and alectinib, AstraZeneca’s durvalumab and mereletinib, Celgene’s/ Clovis’ rociletinib, BMS’s Yervoy, Array’s/AstraZeneca’s selumetinib and AbbVie’s veliparib).
• How the treatment landscape for NSCLC will evolve in the future for each patient segment and line of therapy.

Key Opinion Leaders

KOLs from North America

• Paul Bunn, Distinguished Professor, Division of Medical Oncology, University of Colorado Edward Garon, Associate Professor, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
• Giuseppe Giaccone, Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University, Washington, DC
• Leora Horn, Assistant Professor of Medicine (Haematology/Oncology) and Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Tennessee
• Joan Shiller, Deputy Director of the Simmons Comprehensive Cancer Center and Division Director of Hematology/Oncology, University of Texas-Southwestern Medical Center, Texas
• Mark Socinski, Professor of Medicine and Thoracic Surgery, University of Pittsburgh School of Medicine, Pennsylvania

KOLs from Europe

• Ahmed Awada, Professor and Head of the Medical Oncology Clinic, Jules Bordet Institute, Brussels & Free Universities, Brussels, Belgium
• Federico Cappuzzo, Professor and Director of Medical Oncology, Ospedale Civile di Livorno, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy
• Solange Peters, Head of Thoracic Malignancies Program, Department of Oncology, University of Lausanne, Switzerland
• David Planchard, Associate Professor, Department of Medical Oncology (Thoracic Oncology Group), Gustave-Roussy, France
• Nick Thatcher, previously held the post of Professor of Medical Oncology at the Christie Hospital NHS Trust in Manchester, England
• Anonymous KOL, Germany

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, June 2015.

You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH OBJECTIVES

3. RESEARCH FOCUS

3.1. NSCLC treatment

4. IMMUNOTHERAPY

4.1. Overview
4.2. Marketed drugs
4.3. Opdivo (nivolumab; Bristol-Myers Squibb)
4.4. Pipeline drugs
4.5. Keytruda (pembrolizumab; Merck & Co.)
4.6. Atezolizumab (MPDL3280A; Roche)
4.7. Durvalumab (MEDI4736; AstraZeneca)
4.8. Yervoy (ipilimumab; Bristol-Myers Squibb)

5. EGFR MUTATION-POSITIVE NSCLC

5.1. Overview
5.2. Marketed drugs
5.3. Tarceva/Iressa/Gilotrif (Astellas/Roche/AstraZeneca/Boehringer Ingelheim)
5.4. Pipeline drugs
5.5. Mereletinib (AZD9291; AstraZeneca)
5.6. Rociletinib (CO-1686; Celgene/Clovis Oncology)
5.7. Dacomitinib (PF-00299804; Pfizer/SFJ Pharmaceuticals)
5.8. Patritumab (AMG 888; Amgen/Daiichi Sankyo)

6. ALK-POSITIVE NSCLC

6.1. Overview
6.2. Marketed drugs
6.3. Xalkori (crizotinib; Pfizer)
6.4. Zykadia (ceritinib; Novartis)
6.5. Pipeline drugs
6.6. Alectinib (RO5424802/CH5424802; Roche)

7. ALK AND EGFR MUTATION-NEGATIVE NSCLC

7.1. Overview
7.2. Marketed drugs
7.3. Avastin (bevacizumab; Roche)
7.4. Vargatef (nintedanib; Boehringer Ingelheim)
7.5. Cyramza (ramucirumab; Eli Lilly)
7.6. Pipeline drugs
7.7. Selumetinib (AZD6244; Array/AstraZeneca)
7.8. Veliparib (ABT-888; AbbVie)
7.9. Gemzar (necitumumab; Eli Lilly)
7.1. Bavituximab (Peregrine)
7.10. Abemaciclib (LY2835219; Eli Lilly)
7.11. Ganetespib (STA-9090; Synta)

8. CONCLUSION

8.1. Current and future treatment algorithm

9. APPENDIX

9.1. KOL biographies
9.2. KOLS from North America
9.3. KOLs from Europe